AUROVELA 1/20 Drug Patent Profile

When do Aurovela 1/20 patents expire, and what generic alternatives are available?

Aurovela 1/20 is a drug marketed by Aurobindo Pharma and is included in one NDA.

The generic ingredient in AUROVELA 1/20 is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Summary for AUROVELA 1/20

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	AUROVELA 1/20 at DailyMed

Pharmacology for AUROVELA 1/20

Drug Class	Estrogen Progestin
Mechanism of Action	Estrogen Receptor Agonists

US Patents and Regulatory Information for AUROVELA 1/20

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma	AUROVELA 1/20	ethinyl estradiol; norethindrone acetate	TABLET;ORAL-21	207506-001	Jun 16, 2017	AB	RX	No	No

AUROVELA 1/20 Market Dynamics and Financial Trajectory (2019–2025): Competitive positioning, pricing pressure, and supply/IP exposure

Last updated: July 30, 2026

AUROVELA 1/20 (ethinyl estradiol and norethindrone acetate tablets) sits in a mature, highly generics-exposed US oral contraceptive category. Financial trajectory since the early 2019–2020 window is dominated by (1) generic substitution and payer switching, (2) wholesaler buying-pattern volatility, and (3) episodic supply and product-manufacturing constraints for specific label strengths. From a revenue-risk standpoint, AUROVELA 1/20 behaves like a “low single-digit share” legacy brand with limited upside absent label expansion, a unique dosage form, or an explicit differentiated payer contract.

Because AUROVELA 1/20 is not a biologic and is not protected by a modern exclusivity regime at the product level, the key economic driver is not R&D-led growth. It is formulary access, net price realization, and volume retention versus AB-rated generics and alternative branded OCs.

---

What drives AUROVELA 1/20 demand in US oral contraception markets?

Short answer: AUROVELA 1/20 demand is driven by contraceptive adherence and payer formulary placement, with volume primarily retained through long-standing patient prescriber habits and pharmacy substitution controls rather than through clinical differentiation.

How do payers and pharmacy benefit managers influence volume

Oral contraceptives are typically managed through:

• Tiering rules (preferred vs non-preferred)
• Quantity limits and step edits in some plan designs
• Patient pay copay differentials favoring the lowest-cost AB-rated product

In practice, AUROVELA 1/20 faces continuous competitive pressure from generic EE/norethindrone acetate products that clear claims at lower net prices. The brand’s market survival depends on maintaining preferred status long enough to retain switching-sensitive patients.

What role do wholesaler buying patterns play

Oral contraceptive brands experience category-level stocking swings:

• Demand forecasting at the distributor level
• Anticipatory buys when supply risk emerges (manufacturing downtime, packaging line changes)
• Subsequent destocking that can depress shipped units even when end-user demand is steady

Net result: quarterly sales can swing even without a fundamental demand collapse.

What is the market structure for oral contraceptives

• Multiple AB-rated generics per active ingredient/dose strength
• Common interchangeability among EE/norethindrone acetate strengths and “therapeutic equivalents”
• Competition from both branded and generic products in adjacent EE/progestin combinations

This structure increases price competition and compresses gross-to-net over time.

---

How has pricing and net revenue for AUROVELA 1/20 evolved versus generic EE/norethindrone products?

Short answer: Net pricing pressure is structurally persistent because AUROVELA 1/20 competes with lower-cost AB-rated generics, and PBM contracting typically rebalances toward the cheapest preferred option.

What financial metrics matter most for this category

For mature OCs, the financial trajectory usually tracks:

• Net price per prescription (after rebates and chargebacks)
• Units per prescription (usually stable)
• Gross-to-net ratio trends (rising as payer leverage increases)
• Distribution share and fill-rate stability

In most mature OC segments, gross-to-net rises while list price stagnates or grows slowly, producing flat-to-declining net sales per unit over time.

Why AUROVELA 1/20 experiences margin compression

Even if wholesale acquisition cost (WAC) increases nominally:

• Rebates and incentives rise to defend placement
• Contracting pushes net pricing toward generics
• Pharmacy substitution erodes brand share

That dynamic produces a financial profile that looks like “reduced revenue per prescription” with intermittent unit shocks.

---

When do supply disruptions or manufacturing constraints change AUROVELA 1/20 sales?

Short answer: Sales spikes and subsequent drawdowns typically occur around disruptions: supply shortages can temporarily raise backorder conversions for the available product, followed by normalization and competitive re-switching.

Category-level manufacturing risk

Common triggers:

• Finished dose packaging line constraints
• Raw material procurement delays for EE/progestins
• Quality system events
• Labeling or regulatory changes requiring production holds

For legacy OCs, these risks can drive short, non-linear quarters. Financial trajectory should be analyzed on a trailing-12-month basis rather than single quarters.

---

What patent and exclusivity position affects AUROVELA 1/20 pricing power?

Short answer: AUROVELA 1/20’s long-term economics are weakly tied to patent exclusivity compared with the immediate AB-generic competitive landscape. The product is effectively in a post-exclusivity market where generics set the pricing floor.

Why patent leverage is limited for legacy OCs

Ethinyl estradiol and norethindrone acetate are mature actives with extensive generic competition. For a brand like AUROVELA 1/20, remaining protection (if any) is usually narrow and does not broadly prevent AB-rated competition across the core EE/progestin combination.

What this means for financial trajectory

• Any residual formulation or method-of-use protection would typically affect only a subset of claims, not the “headline” AB ability of generic competitors.
• Economic outcomes are therefore primarily dictated by contracting and substitution.

---

What generic entry risks exist for AUROVELA 1/20 and how do they affect revenue?

Short answer: Generic substitution risk is continuous and already realized for most EE/norethindrone acetate strengths. Remaining entry risk tends to be concentrated in:

• New applicants improving cost structure
• A competitor regaining supply after a disruption
• Re-positioning of preferred formulary tiers

Revenue impact mechanism

Generic entry or aggressive contracting typically:

1. Raises switching rates
2. Forces price concessions (rebates/discounts)
3. Drops brand prescriptions share, with revenue decline lagging by 1 to 2 quarters

In mature OCs, this pattern is more persistent than episodic.

---

How does AUROVELA 1/20 compare with other oral contraceptive brands on financial durability?

Short answer: Brand durability tracks payer preference and supply reliability rather than clinical advantage. Most branded OCs face similar revenue compression once generics dominate share.

What differentiates winners

• Placement on commercial formularies as “preferred brand” despite generic availability
• Lower likelihood of manufacturing constraints
• Contracting that preserves net price per script above a threshold
• Stable patient recall via pharmacy-level substitution controls

AUROVELA 1/20’s outcome in this framework depends on its negotiated position with large PBMs and its ability to maintain supply continuity.

---

What is the competitive landscape for EE/norethindrone acetate tablets around AUROVELA 1/20?

Short answer: The competitive set is dominated by AB-rated generics and low-cost branded alternatives within EE/progestin combinations.

Key competitor categories

• Generic EE/norethindrone acetate tablets (multiple manufacturers)
• Other branded OCs with similar dosing regimens (where formulary position allows)
• Indirect competition from other contraceptive modalities that can siphon a small but persistent share over time (IUDs, implants, injectables)

Business implication

Direct unit competition is driven by AB substitution. Indirect competition affects long-term category growth, but for legacy oral tablets it usually changes mix more than total volume in the near term.

---

How should AUROVELA 1/20 revenue be forecast: scenario framework based on market mechanics

Short answer: Forecasting should be anchored on (1) prescription volume share and (2) net price realization after PBM rebates and chargebacks, with overlays for supply events.

Base-case model logic

• Assume continued share erosion versus preferred low-cost AB products
• Assume net price per script declines gradually with payer renegotiations
• Assume low single-digit net sales decline annually absent supply disruptions

Downside case

• PBM re-tiering or expanded preferred generic list
• Increased gross-to-net via rebate escalation to retain contracts
• Supply instability for AUROVELA 1/20 leading to lost fills

Upside case

• Contract renewal that preserves preferred brand status
• Temporary supply constraints among competing generics (backorder cover)
• Demand normalization after a period of category-level turbulence

---

What does this mean for licensing, litigation, and investment theses tied to AUROVELA 1/20?

Short answer: The main “deal lever” is formulary position and supply continuity, not exclusivity. Litigation or licensing centered on broad OC patents is less likely to be a primary value driver than in newer drug classes.

Commercial and regulatory angles

• Value is captured via commercial contracting and distribution execution
• Regulatory barriers are comparatively low for AB products because actives are mature
• The economic contest is a cost-and-access contest

---

Key Takeaways

• AUROVELA 1/20 operates in a mature EE/norethindrone acetate market where generic substitution and payer tiering are the dominant drivers of financial trajectory.
• Net revenue pressure is structural: gross-to-net typically rises as brands defend formulary placement against lower-cost AB products.
• Quarterly sales volatility is often tied to distributor inventory cycles and episodic supply constraints rather than step-change demand.
• Patent and exclusivity dynamics provide limited pricing leverage in this product class; contract position and supply reliability are the practical levers.

---

FAQs

1. Why do AUROVELA 1/20 sales fluctuate quarter to quarter even when end-user demand seems stable?
   Distributor inventory cycles, backorder cover effects, and supply normalization events typically drive shipment timing.

2. What PBM formulary mechanisms most strongly affect AUROVELA 1/20 net price realization?
   Preferred tier placement, step edits/quantity limits, and rebate structures that shift as generic cheapest-option status changes.

3. How does pharmacist substitution generally affect AUROVELA 1/20 prescription share?
   Pharmacy-level substitution for AB-equivalent generics reduces brand share when patients are not constrained by a brand-only prescription.

4. Does AUROVELA 1/20 face indirect competition from long-acting reversible contraceptives (LARC) more than other OCs?
   Mix impacts exist across oral contraception cohorts, but for mature OCs the larger near-term driver is AB-generic substitution.

5. What indicators best signal an approaching AUROVELA 1/20 revenue decline?
   Contract changes that expand preferred generic lists, rising gross-to-net, and prescription share loss to lower-cost AB products.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Drug Shortages (Archived and Current Shortages). U.S. Food and Drug Administration.
3. IQVIA/Industry market research reports on oral contraceptives (EE/progestin combination) and generic penetration (accessed via public summaries where available).
4. FDA. Guidance for Industry: ANDA Submissions and Therapeutic Equivalence. U.S. Food and Drug Administration.
5. Public PBM formulary and contracting frameworks for specialty and generic tiers (publicly available summaries).